Accurate and early detection of diseases is key to improving healthcare, but current diagnostic tests often lack precision, leading to delays, false alarms, and higher healthcare costs. Our innovative solution uses advanced nanotechnology and CRISPR—a cutting-edge molecular tool—to create ultra-sensitive tests that detect tiny traces of disease markers at very early stages. These tests are designed to work seamlessly with existing hospital equipment, making them easy to adopt across various applications.
This project will assess our technology’s commercial potential. We’ll analyze the market to identify the areas where our diagnostics can deliver the most value, refine the technology in collaboration with clinical and industry experts, and validate it through real-world testing. Additionally, we’ll establish quality standards, secure patents, and build partnerships to scale manufacturing.
Our technology has the potential to transform healthcare, reduce costs, and support better patient outcomes across diverse medical fields by enabling faster and more reliable disease detection.
